GLIBIOLIQUID

R&D Projects

Diagnostic kit from blood sample blood sample in patients with brain tumor

LIQUID BIOPSY NEW MARKERS

This project aims to develop a standardised diagnostic product based on the analysis of the content of Extracellular Vesicles (EVs) in liquid biopsies of patients with brain tumours that allows the presence of IDH1 mutations to be identified.

IDH1 mutations play an important role as a prognostic and predictive biomarker in patients with brain tumours. As stated in the latest international classification of gliomas, patients with tumours with mutations in the IDH1 gene have a better prognosis than their counterparts without said mutations.

1

product detects brain cancer with a blood sample

Patients with tumours with mutations in the IDH1 gene have a better prognosis than other patients.

There is also a new generation of drugs aimed at this target and their efficacy is already being tested in clinical trials. The major commercial limitation for these products is the determination of the mutation, as the procedure to obtain it is clinically irreproducible and costly. Regardless of tumour tissue, the only procedure to identify this target that has been developed so far is through cerebrospinal fluid punctures. This procedure is not standardised and poses a significant risk of brain herniation and death, although the cost in terms of the absence of complications is clearly lower than in brain biopsies.

To achieve the objectives

RTC-2016-4990-1 2016-2019

To ensure the success of the project, a consortium has been set up with the HM Hospitales Research Foundation.

The project is co-funded by the Ministry of Economy and Competitiveness, within the call Challenges-Collaboration of the State Programme for Research, Development and Innovation Oriented to the Challenges of Society, in the framework of the State Plan for Scientific and Technical Research and Innovation 2013-2016, and by the European Regional Development Fund (ERDF).